Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: RB1CC1

Gene summary for RB1CC1

Gene summary.

Gene information	Species	Human
	Gene symbol	RB1CC1
	Gene ID	9821
	Gene name	RB1 inducible coiled-coil 1
	Gene Alias	ATG17
	Cytomap	8q11.23
	Gene Type	protein-coding
	GO ID	GO:0000045
	UniProtAcc	Q8TDY2

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
9821	RB1CC1	LZE2T	Human	Esophagus	ESCC	8.71e-08	1.32e+00	0.082
9821	RB1CC1	LZE4T	Human	Esophagus	ESCC	5.22e-30	1.22e+00	0.0811
9821	RB1CC1	LZE7T	Human	Esophagus	ESCC	7.48e-04	4.47e-01	0.0667
9821	RB1CC1	LZE8T	Human	Esophagus	ESCC	1.80e-10	4.12e-01	0.067
9821	RB1CC1	LZE20T	Human	Esophagus	ESCC	4.15e-10	7.17e-01	0.0662
9821	RB1CC1	LZE22D1	Human	Esophagus	HGIN	2.09e-02	-7.59e-02	0.0595
9821	RB1CC1	LZE22T	Human	Esophagus	ESCC	2.57e-08	3.69e-01	0.068
9821	RB1CC1	LZE24D1	Human	Esophagus	HGIN	4.62e-02	4.39e-01	0.054
9821	RB1CC1	LZE24T	Human	Esophagus	ESCC	2.10e-28	1.09e+00	0.0596
9821	RB1CC1	LZE21T	Human	Esophagus	ESCC	1.54e-06	4.53e-01	0.0655
9821	RB1CC1	LZE6T	Human	Esophagus	ESCC	1.87e-02	1.30e-01	0.0845
9821	RB1CC1	P1T-E	Human	Esophagus	ESCC	3.48e-07	7.50e-01	0.0875
9821	RB1CC1	P2T-E	Human	Esophagus	ESCC	2.32e-52	1.20e+00	0.1177
9821	RB1CC1	P4T-E	Human	Esophagus	ESCC	6.64e-35	9.64e-01	0.1323
9821	RB1CC1	P5T-E	Human	Esophagus	ESCC	4.15e-06	1.35e-01	0.1327
9821	RB1CC1	P8T-E	Human	Esophagus	ESCC	5.31e-29	8.36e-01	0.0889
9821	RB1CC1	P9T-E	Human	Esophagus	ESCC	3.89e-18	6.65e-01	0.1131
9821	RB1CC1	P10T-E	Human	Esophagus	ESCC	2.52e-33	7.26e-01	0.116
9821	RB1CC1	P11T-E	Human	Esophagus	ESCC	1.49e-18	9.54e-01	0.1426
9821	RB1CC1	P12T-E	Human	Esophagus	ESCC	5.27e-70	1.80e+00	0.1122

Page: 1 2 3 4 5 6 7 8 9

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:000609120	Esophagus	HGIN	generation of precursor metabolites and energy	145/2587	490/18723	3.41e-20	2.04e-17	145
GO:001598020	Esophagus	HGIN	energy derivation by oxidation of organic compounds	105/2587	318/18723	1.16e-18	4.99e-16	105
GO:200123327	Esophagus	HGIN	regulation of apoptotic signaling pathway	97/2587	356/18723	1.36e-11	1.57e-09	97
GO:001623616	Esophagus	HGIN	macroautophagy	77/2587	291/18723	7.15e-09	4.61e-07	77
GO:002241120	Esophagus	HGIN	cellular component disassembly	102/2587	443/18723	8.31e-08	4.33e-06	102
GO:200123427	Esophagus	HGIN	negative regulation of apoptotic signaling pathway	59/2587	224/18723	4.68e-07	2.07e-05	59
GO:19030089	Esophagus	HGIN	organelle disassembly	36/2587	114/18723	8.60e-07	3.58e-05	36
GO:009719126	Esophagus	HGIN	extrinsic apoptotic signaling pathway	56/2587	219/18723	2.48e-06	8.80e-05	56
GO:000042216	Esophagus	HGIN	autophagy of mitochondrion	25/2587	81/18723	5.95e-05	1.38e-03	25
GO:006172616	Esophagus	HGIN	mitochondrion disassembly	25/2587	81/18723	5.95e-05	1.38e-03	25
GO:00070336	Esophagus	HGIN	vacuole organization	44/2587	180/18723	8.97e-05	1.96e-03	44
GO:004873225	Esophagus	HGIN	gland development	88/2587	436/18723	1.34e-04	2.71e-03	88
GO:19050375	Esophagus	HGIN	autophagosome organization	28/2587	103/18723	2.58e-04	4.53e-03	28
GO:006100820	Esophagus	HGIN	hepaticobiliary system development	37/2587	150/18723	2.58e-04	4.53e-03	37
GO:000188920	Esophagus	HGIN	liver development	36/2587	147/18723	3.61e-04	5.68e-03	36
GO:200123626	Esophagus	HGIN	regulation of extrinsic apoptotic signaling pathway	36/2587	151/18723	6.20e-04	8.58e-03	36
GO:00000455	Esophagus	HGIN	autophagosome assembly	26/2587	99/18723	7.45e-04	9.90e-03	26
GO:00619128	Esophagus	HGIN	selective autophagy	19/2587	68/18723	1.68e-03	1.85e-02	19
GO:200123725	Esophagus	HGIN	negative regulation of extrinsic apoptotic signaling pathway	23/2587	97/18723	5.91e-03	4.78e-02	23
GO:2001233111	Esophagus	ESCC	regulation of apoptotic signaling pathway	256/8552	356/18723	4.11e-24	1.04e-21	256

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa0501630	Esophagus	HGIN	Huntington disease	129/1383	306/8465	6.81e-28	7.41e-26	5.88e-26	129
hsa0501430	Esophagus	HGIN	Amyotrophic lateral sclerosis	140/1383	364/8465	2.13e-25	1.16e-23	9.19e-24	140
hsa0502230	Esophagus	HGIN	Pathways of neurodegeneration - multiple diseases	153/1383	476/8465	1.22e-18	4.41e-17	3.50e-17	153
hsa0501030	Esophagus	HGIN	Alzheimer disease	130/1383	384/8465	5.26e-18	1.71e-16	1.36e-16	130
hsa0501727	Esophagus	HGIN	Spinocerebellar ataxia	43/1383	143/8465	2.68e-05	3.64e-04	2.89e-04	43
hsa05016113	Esophagus	HGIN	Huntington disease	129/1383	306/8465	6.81e-28	7.41e-26	5.88e-26	129
hsa05014113	Esophagus	HGIN	Amyotrophic lateral sclerosis	140/1383	364/8465	2.13e-25	1.16e-23	9.19e-24	140
hsa05022113	Esophagus	HGIN	Pathways of neurodegeneration - multiple diseases	153/1383	476/8465	1.22e-18	4.41e-17	3.50e-17	153
hsa05010113	Esophagus	HGIN	Alzheimer disease	130/1383	384/8465	5.26e-18	1.71e-16	1.36e-16	130
hsa05017112	Esophagus	HGIN	Spinocerebellar ataxia	43/1383	143/8465	2.68e-05	3.64e-04	2.89e-04	43
hsa05014210	Esophagus	ESCC	Amyotrophic lateral sclerosis	266/4205	364/8465	1.31e-20	2.20e-18	1.13e-18	266
hsa05016210	Esophagus	ESCC	Huntington disease	226/4205	306/8465	1.38e-18	8.72e-17	4.46e-17	226
hsa05022210	Esophagus	ESCC	Pathways of neurodegeneration - multiple diseases	318/4205	476/8465	6.10e-15	2.04e-13	1.05e-13	318
hsa05010210	Esophagus	ESCC	Alzheimer disease	263/4205	384/8465	1.80e-14	5.47e-13	2.80e-13	263
hsa0414010	Esophagus	ESCC	Autophagy - animal	101/4205	141/8465	7.60e-08	6.21e-07	3.18e-07	101
hsa0501728	Esophagus	ESCC	Spinocerebellar ataxia	94/4205	143/8465	6.77e-05	2.90e-04	1.48e-04	94
hsa0421114	Esophagus	ESCC	Longevity regulating pathway	58/4205	89/8465	2.19e-03	6.16e-03	3.16e-03	58
hsa0501438	Esophagus	ESCC	Amyotrophic lateral sclerosis	266/4205	364/8465	1.31e-20	2.20e-18	1.13e-18	266
hsa0501638	Esophagus	ESCC	Huntington disease	226/4205	306/8465	1.38e-18	8.72e-17	4.46e-17	226
hsa0502238	Esophagus	ESCC	Pathways of neurodegeneration - multiple diseases	318/4205	476/8465	6.10e-15	2.04e-13	1.05e-13	318

Page: 1 2 3 4 5 6

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

RB1CC1

SNV

Missense_Mutation

novel

c.1784N>A

p.Pro595Gln

p.P595Q

Q8TDY2

protein_coding

deleterious(0.04)

possibly_damaging(0.832)

TCGA-A7-A0DB-01

Breast

breast invasive carcinoma

Female

<65

I/II

Hormone Therapy

arimidex

RB1CC1

SNV

Missense_Mutation

novel

c.3995N>G

p.Phe1332Cys

p.F1332C

Q8TDY2

protein_coding

deleterious(0)

probably_damaging(0.996)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

RB1CC1

SNV

Missense_Mutation

c.3428N>T

p.Arg1143Ile

p.R1143I

Q8TDY2

protein_coding

deleterious_low_confidence(0)

possibly_damaging(0.888)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

RB1CC1

SNV

Missense_Mutation

novel

c.1511N>C

p.Val504Ala

p.V504A

Q8TDY2

protein_coding

deleterious(0)

probably_damaging(0.978)

TCGA-B6-A0RS-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

RB1CC1

SNV

Missense_Mutation

c.3922G>A

p.Glu1308Lys

p.E1308K

Q8TDY2

protein_coding

tolerated(0.81)

benign(0.212)

TCGA-BH-A0E2-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

doxorubicin

RB1CC1

SNV

Missense_Mutation

c.4472G>A

p.Arg1491Lys

p.R1491K

Q8TDY2

protein_coding

deleterious(0.02)

probably_damaging(0.979)

TCGA-BH-A0GZ-01

Breast

breast invasive carcinoma

Female

<65

I/II

Hormone Therapy

arimidex

RB1CC1

SNV

Missense_Mutation

rs145052579

c.992N>T

p.Ser331Phe

p.S331F

Q8TDY2

protein_coding

deleterious(0)

probably_damaging(0.996)

TCGA-BH-A0HF-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

arimidex

RB1CC1

SNV

Missense_Mutation

novel

c.1036N>A

p.Glu346Lys

p.E346K

Q8TDY2

protein_coding

deleterious(0)

benign(0.073)

TCGA-D8-A1JE-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

adriamicin

RB1CC1

SNV

Missense_Mutation

c.983G>T

p.Cys328Phe

p.C328F

Q8TDY2

protein_coding

deleterious(0)

probably_damaging(0.994)

TCGA-D8-A1JH-01

Breast

breast invasive carcinoma

Female

<65

I/II

Hormone Therapy

nolvadex

RB1CC1

SNV

Missense_Mutation

c.629N>A

p.Arg210Lys

p.R210K

Q8TDY2

protein_coding

deleterious(0.03)

benign(0.437)

TCGA-E2-A1LH-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

adriamycin

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1